Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-11-08
1991-05-07
Robinson, Allen J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
050137395
ABSTRACT:
Chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic fatigue syndrome, chronic inflammatory connective tissue disease, including rheumatoid arthritis and systemic lupus erythematous and related diseases, and multiple sclerosis are treated by the administration via a pharmacologically effective route of an essentially pure opiate receptor antagonist, preferably an essentially pure opiate receptor antagonist exhibiting a substantially higher blocking effectiveness against Mu opiate receptor sites than against Delta receptor sites, exemplified by naltrexone and naloxone, at a low dose concentration, corresponding to about 1-10 mg per day for naltrexone, at which concentration Delta blocking activity is small, while Mu blocking activity is significant.
REFERENCES:
patent: 4537878 (1985-08-01), Plotnikoff
patent: 4857533 (1989-08-01), Sherman et al.
patent: 4863928 (1989-10-01), Atkinson
Prieto, J. et al., Naloxone Reversable Monocyte Dysfunction in Patients with Chronic Fatigue Syndrome, Scand J Immonol 30(1):13-20 (1989) (Abstract).
Bihari Bernard
Drury Finvola
Daniel William J.
Hollinden Gary E.
Robinson Allen J.
LandOfFree
Method of treating chronic fatigue syndrome using an opiate rece does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating chronic fatigue syndrome using an opiate rece, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating chronic fatigue syndrome using an opiate rece will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-939863